Abstract
The utility of radioiodine pre-remnant ablation scans remains very controversial. This chapter argues for performing radioiodine pre-remnant ablation scans. There are five main arguments that are typically presented against the utility of pre-remnant ablation scans: (1) “no useful data is obtained from pre-remnant ablation radioiodine scans that will alter my management,” (2) “everything I need to know is on the post-therapy scan,” (3) stunning, (4) the potential benefit is not worth the costs or inconveniences, and (5) until data are published demonstrating that the pre-131I therapy scans alter patient outcomes, these scans should not be performed. This chapter presents a point by counterpoint discussion of the arguments for and against pre-therapy radioiodine ablation. The chapter concludes with rarely discussed issues that in my opinion may be important points regarding the differences in opinions of the utility of pre-remnant ablation radioiodine scans.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Haugen B, Alexander E, Bible K, Doherty G, Mandel S, Nikiforov Y, Pacini F, Randolph G, Sawka A, Schlumberger M, Schuff K, Sherman S, Sosa J, Steward D, Tuttle, R, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1–133.
Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JWA, Wiersinga W, European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787–803.
National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology. Thyroid carcinoma. Follicular thyroid carcinoma. V.2.2013.
British Thyroid Association and Royal College of Physicians. Guidelines/statements the British Thyroid Association 2014 edition of the Thyroid Cancer Guidelines (Draft). Available at: http://www.british-thyroid-association.org/Guidelines/.
Silberstein EB, Alvai A, Balon H, et al. The SNM pracice guideline for therapy of thyroid disease with 131I, 3.0. J Nucl Med. 2012;53:1633–51.
Van Nostrand D, Aiken M, Atkins F, Moreau S, Garcia C, Acio E, Burman K, Wartofsky L. The utility of radioiodine scans prior to 131I ablation in patients with well-differentiated thyroid cancer. Thyroid. 2009;19:849–55.
Chen MK, Yasrebi M, Samii J, Staib LH, Doddamane I, Cheng DW. The utility of I-123 pretherapy scan in I-131 radioiodine therapy for thyroid cancer. Thyroid. 2012;22:304–9.
McDougall IR. Differentiated thyroid cancer. In: McDougall IR, editor. Management of thyroid cancer and related nodular disease. London: Springer; 2006. p. 173.
Amdur RJ, Mazzaferri EL. The role of a diagnostic radioiodine whole body scan (DxSCAN). In: Amdur RJ, Mazzaferri E, editors. Essentials of thyroid cancer management. Springer: New York; 2005. p. 63.
Haq MS, Harmer C. Non-surgical management of thyroid cancer. In: Mazzaferri E, Harmer C, Mallick UK, Kendall-Taylor P, editors. Practical management of thyroid cancer. London: Springer; 2006. p. 174.
Schlumberger MJ, Leboulleux SM, Pacini F. Follow-up of patients with differentiated thyroid carcinoma. In: Mazzaferri EL, Harmer C, Mallick UJ, Kendall-Taylor P, editors. Practical management of thyroid cancer. New York: Springer; 1996. p. 231.
Schlumberger MJ, Pacini F. The low utility of pretherapy scans in thyroid cancer patients. Thyroid. 2009;19:815–6.
McDougall IR. The case for obtaining a diagnostic whole-body scan prior to iodine 131 treatment of differentiated thyroid cancer. Thyroid. 2009;19:811–3.
Spanu A, Solinas ME, Chessa F, Sanna D, Nuvoli S, Madeddu S. 131I SPECT-CT in the follow-up of differentiated thyroid carcinoma: incremental value versus planar imaging. J Nucl Med. 2009;50:184–90.
Tharp K, Israel O, Hausmann J, Bettman L, Martin WH, Daitzchman M, Sandler MP, Delbeke D. Impact of 131I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2004;31:1435–42.
Hilditch TE, Dempsey MF, Bolster AA, McMenemin RM, Reed NS. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I. Eur J Nucl Med Mol Imaging. 2002;29:783–8.
Gerard SK, Park HM. Stunning and I-123 use for diagnostic whole body scanning: letter to the editor. Thyroid. 2006;16:817.
MIRD (Medical Internal Radiation Dose) Committee 1975 Report #5. Summary of current radiation dose estimates to humans from 123I, 124I, 125I, 126I, 130I, 131I, and 132I as sodium iodide. J Nucl Med. 1975; 16:857–60.
Lundh C, Lindencrona U, Postgard P, Carlsson T, Nilsson M, Forssell-Aronsson E. Radiation-induced thyroid stunning: differential effects of 123I, 131 I, 99mTc, and 211AT on iodide transport and NIS mRNA expression in cultured thyroid cells. J Nucl Med. 2009;50:116–1171.
McDougall IR, Iagaru A. Thyroid stunning: fact or fiction. Sem Nucl Med. 2011;41:105–12.
Bahk YW, editor. Combined scintigraphic and radiographic diagnosis of bone and joint diseases. 2nd ed. Berlin: Springer; 2000.
Kulkarni K, Van Nostrand D, Young-Rok S, Aiken M, Mete M, Burman K, Wartofsky L. Detectability of foci of radioiodine uptake in the thyroid bed and neck comparing pinhole with parallel-hole collimators. Nuc Med Comm. 2011;32:369–74.
Chennupati S, Van Nostrand D, Kharazi P, Khorjekar G. Determination of the number of foci of normal thyroid tissue remaining after thyroidectomy in patients with differentiated thyroid cancer: the Washington hospital center experience. J Nucl Med. 2011;52S:1300.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this chapter
Cite this chapter
Van Nostrand, D. (2016). To Perform or Not to Perform Radioiodine Scans Prior to 131I Remnant Ablation? PRO. In: Wartofsky, L., Van Nostrand, D. (eds) Thyroid Cancer. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-3314-3_19
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3314-3_19
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-3312-9
Online ISBN: 978-1-4939-3314-3
eBook Packages: MedicineMedicine (R0)